Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1-mutated acute myeloid leukemia.
10.1016/j.apsb.2022.10.018
- Author:
Yin FENG
1
;
Yefan HAN
1
;
Anni HU
1
;
Yi QU
1
;
Yili HU
2
;
Hao WU
1
;
Xinzhi WANG
1
;
Li HE
3
Author Information
1. College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, China.
2. Experiment Center for Science and Technology, Nanjing University of Chinese Medicine, Nanjing 210046, China.
3. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Publication Type:Journal Article
- Keywords:
Acute myeloid leukemia;
Covalent;
Differentiation;
Heliangin;
NPM1-mutation;
Pre-rRNA;
RPS2;
p53 stabilization
- From:
Acta Pharmaceutica Sinica B
2023;13(2):598-617
- CountryChina
- Language:English
-
Abstract:
Although NPM1 mutations are frequently found in acute myeloid leukemia patients, therapeutic strategies are scarce and unsuitable for those who cannot tolerate intensive chemotherapy. Here we demonstrated that heliangin, a natural sesquiterpene lactone, exerts favorable therapeutic responses in NPM1 mutant acute myeloid leukemia cells, with no apparent toxicity to normal hematogenous cells, by inhibiting their proliferation, inducing apoptosis, causing cell cycle arrest, and promoting differentiation. In-depth studies on its mode of action using quantitative thiol reactivity platform screening and subsequent molecular biology validation showed that the ribosomal protein S2 (RPS2) is the main target of heliangin in treating NPM1 mutant AML. Upon covalent binding to the C222 site of RPS2, the electrophilic moieties of heliangin disrupt pre-rRNA metabolic processes, leading to nucleolar stress, which in turn regulates the ribosomal proteins-MDM2-p53 pathway and stabilizes p53. Clinical data shows that the pre-rRNA metabolic pathway is dysregulated in acute myeloid leukemia patients with the NPM1 mutation, leading to a poor prognosis. We found that RPS2 plays a critical role in regulating this pathway and may be a novel treatment target. Our findings suggest a novel treatment strategy and lead compound for acute myeloid leukemia patients, especially those with NPM1 mutations.
